Gene Editing
-
Ravi Kapoor Joins SOHM, Inc. Board as Independent Director
SOHM, Inc. appointed Ravi Kapoor as an Independent Director. Kapoor brings over 30 years of experience in corporate law, M&A, and financial management. His expertise is expected to enhance SOHM’s strategic direction, corporate governance, and growth initiatives, particularly aligning with the company’s focus on generic drugs and gene-editing technologies.
-
Lilly to Acquire Verve Therapeutics to Develop One-Time Cardiovascular Therapies for High-Risk Patients
Eli Lilly will acquire Verve Therapeutics, a clinical-stage company focused on gene editing therapies for cardiovascular disease. The deal, valued at approximately $1 billion, aims to advance Verve’s one-time treatment approach targeting genes linked to heart disease. Lilly plans to leverage its expertise in cardiometabolic diseases and gene medicines to develop Verve’s pipeline, including VERVE-102.
